Dompé Farmaceutici S.p.A

Dompé Farmaceutici S.p.A is a biopharmaceutical company based in Italy. The company was founded in 1940 by Alberto Dompé, a pharmacist and entrepreneur who wanted to improve the quality of life of patients through science and technology. Today, Dompé is led by his grandson, Sergio Dompé, who shares the same vision and passion for making a difference in healthcare.

Dompé has its headquarters in Milan, Italy, and operates in several countries around the world, including the US, Canada, China, Albania, and Switzerland. The company has a market cap of about $2.4B as of May 2023 and employs more than 800 people, most of whom are scientists and researchers.

Dompé's product portfolio includes drugs for primary and specialty care, such as diabetes, cardiovascular diseases, ophthalmology, and dermatology. The company also has a strong pipeline of projects in the fields of nerve growth factor (NGF), gene therapy, and artificial intelligence. One of its most promising projects is Exscalate, a platform that uses supercomputers and machine learning to design new drugs for various diseases, including COVID-19.

Dompé has received several awards and recognitions for its achievements and contributions to the biopharmaceutical industry. In 2021, the company was ranked among the top 10 most innovative companies in Europe by Fast Company magazine. In 2022, Dompé was awarded the European Biotech Leadership Award by Euronext for its outstanding performance and growth. In 2023, Dompé was named one of the World's Best Employers by Forbes magazine for its culture of innovation and diversity.

Foundation: 1940

Headquarters: Milan, Italy

Website: https://www.dompe.com/